Thursday, January 13, 2011
MedImmune LLC, of Gaithersburg, Md., and Micromet Inc., of Bethesda, Md., began Phase I trials of MEDI-565 (MT111) in advanced gastrointestinal cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.